Highest-materiality recent filing
Processa's binding term sheet with Intact Therapeutics for PCS12852 expires without deal
Binding Term Sheet dated June 17, 2025 with Intact Therapeutics expired February 12, 2026.
Processa shareholders approve 10x authorized share increase and reverse split
Shareholders approved increase in authorized common shares from 100M to 1B (13.7M for, 3.0M against).
Processa shareholders approve 10x increase in authorized shares, reverse split up to 1:50
Approved increase of authorized common shares from 100M to 1B (13.7M for, 3.0M against).
On July 25, 2025, Processa filed a prospectus supplement to its Form S-3 (Registration No. 333-279588) for an equity distribution agreement with A.G.P./Alliance Global Partners.
Terminated licensing agreement with Ocuphire Pharma (now Opus Genetics) for PCS3117, returning rights to original licensor.
Processa prices $7M public offering of common stock and warrants at $0.25/unit
Gross proceeds of $7M before expenses; offering of 28M shares/pre-funded warrants plus 28M common warrants.
Near-term payments: $2.5M option exercise fee plus 3.5% equity stake in Intact upon closing.
Processa receives Nasdaq bid-price deficiency notice; 180 days to regain compliance
Nasdaq notified Processa that common stock bid price closed below $1.00 for 30 consecutive business days.
Processa closes $5M public offering; Series A/B warrants at $0.65 exercise price
Gross proceeds of $5.0M from offering closed Jan 29, 2025; net proceeds for general corporate purposes.
Processa provides pipeline update, Q2 net loss $3.0M; Phase 2 NGC-Cap trial underway
FDA cleared IND for NGC-Cap Phase 2 in July 2024; multicenter trial in metastatic breast cancer initiated, initial data expected mid-2025.
FDA clears IND for Processa's NGC-Cap Phase 2 trial in breast cancer
FDA cleared IND for NGC-Cap Phase 2 trial in advanced/metastatic breast cancer.
Processa appoints Russell Skibsted as CFO; James Stanker retires
Russell Skibsted appointed CFO effective July 16, 2024; succeeds James Stanker who retired.
Processa presents NGC-Cap Phase 1b data at AACR; poster modified
David Young, President R&D, presented two abstracts at AACR 2024 on NGC-Cap and Project Optimus.
Processa regains Nasdaq minimum bid price compliance; delisting risk resolved
Received written notice from Nasdaq on Feb 6, 2024 confirming compliance with Listing Rule 5550(a)(2).
Processa Pharmaceuticals prices $7M public offering of 1.56M shares and warrants at $4.50 per unit
Pricing of 1,555,555 shares (or pre-funded warrants) and common warrants at $4.50 per unit; gross proceeds ~$7M.
Processa completes Phase 1b of NGC-Cap; recommends two Phase 2 doses for advanced breast cancer
Phase 1b trial in 18 advanced GI cancer patients achieved 2-10x greater 5-FU exposure than FDA-approved capecitabine.
Processa expands NGC-Cap into breast cancer; FDA agrees existing data supports Phase 2 trial
FDA agreed existing data can directly support Phase 2 breast cancer trial design.
Processa Pharmaceuticals to effect 1-for-20 reverse stock split to regain Nasdaq compliance
Reverse split ratio 1-for-20, effective 12:01 a.m. ET Jan. 22, 2024.
NGC-Cap doses: 75-225 mg twice daily vs capecitabine's 1600-2500 mg twice daily; 5-FU exposure up to 10x greater.
Nasdaq grants Processa second 180-day grace period to meet $1.00 bid price rule
Received Nasdaq letter on Sept 19; second compliance period ends March 18, 2024.
Processa Pharmaceuticals appoints George Ng as CEO; COO Floyd to resign Aug 31
George Ng appointed CEO and director effective Aug 8, 2023; previously president/COO of Calidi Biotherapeutics.
Processa increases authorized common shares to 100M; all director nominees elected at annual meeting
Shareholders approved amendment to increase authorized common stock from 50M to 100M shares.
On April 30, 2026, Processa Pharmaceuticals, Inc. (the “Company”) approved a transition in the employment status of Dr. Sian Bigora, the Company’s Chief Development and Regulatory Officer, as part of her planned transition toward retirement.
by mutual agreement, James Stanker resigned as Chief Financial Officer of the Company, effective July 15, 2024.
announced the appointment of Mr. Russell Skibsted, Effective July 16, 2024 as its Chief Financial Officer.
announcing that Virgil Thompson, age 83, a member of the Company’s Board of Directors and Chairman of our Nominating and Governance Committee, unexpectedly passed away on Thursday November 9, 2023.
announced the appointment of Mr. George Ng as its Chief Executive Officer and a director.
Dr. David Young will continue with the Company as a member of the Board of Directors and as the Company’s President of Research and Development.
announced the appointment of Mr. George Ng as its Chief Executive Officer and a director.
Mr. R. Michael Floyd resigned as Chief Operating Officer of the Company, effective August 31, 2023.
On July 19, 2022, the Board of Directors of Processa Pharmaceuticals, Inc. (the “Company”) appointed James R. Neal to its Board of Directors, effective immediately.
Dr. Khalid Islam, who served as a member of the Board of Directors of the Company (the “Board”) since November 2020, retired from the Board Company effective as of the Annual Meeting.
Max materiality 0.80 · Median 0.55 · Most common event other_material